Serum Ustekinumab Concentrations Are Associated With Improved Outcomes With the Magnetic Resonance Index of Activity for Crohn's Disease

Kaylie Chen; Johnson Chen; Emily Smith; Prerna Mathani; Randy Longman; Dana Lukin; Ellen Scherl; Juliette Gerber; Robert Battat

doi:10.1093/ibd/izac236

Serum Ustekinumab Concentrations Are Associated With Improved Outcomes With the Magnetic Resonance Index of Activity for Crohn's Disease

Inflamm Bowel Dis. 2023 Sep 1;29(9):1499-1503. doi: 10.1093/ibd/izac236.

Authors

Kaylie Chen¹, Johnson Chen², Emily Smith¹, Prerna Mathani¹, Randy Longman¹, Dana Lukin¹, Ellen Scherl¹, Juliette Gerber¹, Robert Battat^{1

3}

Affiliations

¹ Division of Gastroenterology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
² Department of Radiology, Weill Cornell Medical College, New York, NY, USA.
³ Division of Gastroenterology and Hepatology, Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, Quebec, Canada.

PMID: 36421052
DOI: 10.1093/ibd/izac236

No abstract available

Plain language summary

Higher ustekinumab concentrations were associated with improved radiologic (Simplified Magnetic Resonance Index of Activity for Crohn’s Disease) and stringent biomarker (calprotectin) outcomes. The high concentration needed for these novel endpoints validates previous studies using the same assay.

MeSH terms

Antibodies, Monoclonal
Crohn Disease* / drug therapy
Humans
Magnetic Resonance Imaging
Magnetic Resonance Spectroscopy
Remission Induction
Treatment Outcome
Ustekinumab* / therapeutic use

Substances

Ustekinumab
Antibodies, Monoclonal